Eurostar project, AFFILUTIN, 9133, Affibody AB
|Funding from Vinnova||SEK 4 435 470|
|Project duration||October 2014 - September 2017|
|Call||Eurostars medfinansiering 2014-2015|
Purpose and goal
Multiple myeloma is a non-curable blood cancer. In 2010 74.000 people died, globally, of the disease. The goal of this project is to make a new medicine, AFFILUTIN; that can treat multiple myeloma more efficiently and with less side effects than today’s treatments.
Expected results and effects
AFFILUTIN consists of a small protein molecule that binds specifically to a surface moiety of cancer cells, and a radioactive metal that will irradiate the cancer cells from within the body. AFFILUTIN will be injected into the blood of the patients and irradiate the cancer cells with minimal damage to surrounding healthy normal tissues.
Planned approach and implementation
Cancer cell targeting molecules are developed in iterative rounds of selection and optimization to create molecules with best possible binding properties for specific delivery of radiation. Promising tumour seeking capability of derived molecules is confirmed in an animal model of multiple myeloma, encouraging transition into expanded production and further analyses on their therapeutic effect in an animal model.